top of page
  • Writer's pictureAbacus Research

Steris (STE)

Steris is a high quality sterilisation business, with ~6.5% sustainable organic growth due to pricing power and volume growth. Regarding business positioning, there is little not to like. 

We would argue that Steris has all the markings of compounder, and has got to the point where the balance sheet has delevered and synergies have run out, therefore a deal or share buy backs should be on the cards. 

Ethylene Oxide is causing a lot of concern, however we are unconcerned by the EPA's focus as we do not see Ethylene Oxide as a risk for Steris Unfortunately, as for many other defensives, we find the risk reward balanced. 

Potential Upside: $174(+16%)

Sensible Downside: $122(-20%)

Recent Posts

See All

Fortive: potential14% IRR

Fortive is a high quality business with an asset light model, high margins, high incremental margins and consistent FCF generation that is reinvested in M&A. Recent guidance for slow organic growth fo

Vertiv (VRT) - Datacentre play on AI theme

Vertiv is a leader in critical infrastructure for datacentres and a clear beneficiary of AI driven growth. AI tailwind for datacentres is only starting. To date, Vertiv has seen little to no impact fr

Palantir (PLTR)

The advent of LLM’s have changed Palantir's relationships with institutions – the commercial market is now open to what Palantir is selling. This is a significant change from one year ago. AIP bootcam


bottom of page